Liver diseases biochemical mechanisms and new therapeutic insights 1 Pathways, mediators and regulation
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Enfield, NH [u.a.]
Science Publ.
2006
|
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis Klappentext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
MARC
| LEADER | 00000nam a2200000 cc4500 | ||
|---|---|---|---|
| 001 | BV023023153 | ||
| 003 | DE-604 | ||
| 005 | 20080125 | ||
| 007 | t| | ||
| 008 | 071127s2006 xx ad|| |||| 00||| eng d | ||
| 020 | |a 1578084008 |9 1-57808-400-8 | ||
| 035 | |a (OCoLC)61351602 | ||
| 035 | |a (DE-599)BVBBV023023153 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 050 | 0 | |a RC846.9 | |
| 082 | 0 | |a 616.3/62 |2 22 | |
| 245 | 1 | 0 | |a Liver diseases |b biochemical mechanisms and new therapeutic insights |n 1 |p Pathways, mediators and regulation |c ed.: Shakir Ali ... |
| 264 | 1 | |a Enfield, NH [u.a.] |b Science Publ. |c 2006 | |
| 300 | |a XIX, 242 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 650 | 4 | |a Liver Diseases | |
| 650 | 4 | |a Liver |x Pathophysiology | |
| 700 | 1 | |a Ali, Shakir |e Sonstige |4 oth | |
| 773 | 0 | 8 | |w (DE-604)BV023023150 |g 1 |
| 856 | 4 | 2 | |m Digitalisierung UB Regensburg |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016227175&sequence=000003&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 856 | 4 | 2 | |m Digitalisierung UB Regensburg |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016227175&sequence=000004&line_number=0002&func_code=DB_RECORDS&service_type=MEDIA |3 Klappentext |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-016227175 | |
Datensatz im Suchindex
| _version_ | 1819609795377758208 |
|---|---|
| adam_text | Contents
Preface
ό
About the Editors
xiii
About the Authors
xv
Volume
—1
Section
-
L
Liver Diseases: Mediators and Regulation
1.
Collagen Gene Regulation in the Hepatic Stellate Cell
3-26
Branko
Stefanovic and Richard A.
Rippe (USA)
Introduction
3
Molecular mechanisms controlling collagen synthesis
5
Mediators influencing collagen expression in HSCs
10
Posttranscriptional regulation of type I collagen expression
13
2.
CYP2E1
—
Biochemical and Toxicological Aspects and Role in Alcohol-induced Liver Injury
27-44
Arthur I. Cederbaum (USA)
Introduction
27
CYP2E1
29
CYP2E1 and alcohol-induced liver injury
35
Biochemical and toxicological properties of CYP2E1 in HEPG2 cells
35
Future perspectives
38
3.
Alcohol and Methyl Transfer: Implications for Alcohol-related Hepatocarcinogenesis
45-58
Felix Stickel (Switzerland),
Christoph Herold,
Helmut
К.
Seitz and
Detlef
Schuppan (Germany)
Introduction
45
Alcohol-related hepatocarcinogenesis: A multi-step process
46
Mechanisms of alcohol
toxicity
47
Lipotropes as a target of alcohol
toxicity
47
SAMe
for chemoprevention in hepatocarcinogenesis
54
Conclusion
54
4.
Methionine
Adenosyltransf
erase and
S-adenosyłmethionine
in Liver Health and Disease
59-78
Shelly
С
Lu
and
José M.
Mato
(USA)
Introduction
59
Historical
perspective
60
Hepatic methionine metabolism
61
MAT genes and enzyme isof
orms
61
Abnormalities of MAT in liver disease
62
Mechanisms of altered MAT gene expression in liver cirrhosis and cancer
65
SAMe
as control switch in maintaining normal liver function
66
Importance of MAT and
SAMe
in liver disease
—
lessons learned from the
ΜΑΤΙΑ
null mice
68
Concluding remarks
72
Vili
LIVER DISEASES
5.
Acetone Metabolism in the Liver: Two Approaches to the Same Phenomenon
79-92
Med. Habil.
Miklós Péter Kalapos (Hungary)
Introduction and history
79
Metabolic pathways for acetone and role of liver
80
Effects of acetone on
biotransformation
of xenobiotics
82
Summary of clinical implications
84
Possible pathophysiological role(s) of acetone
biodégradation:
two approaches to the same phenomenon
86
Conclusion, perspectives and unanswered questions
87
6.
Oxidative Stress and Liver Fibrosis: From Liver Injury to Modulation of Cell Signalling and Response
93-114
Elena
Zamara,
Erica
Novo
and
Maurizio Parola
(Italy)
Introduction
94
Oxidative stress, liver fibrosis, and chronic liver diseases: major concepts
96
Major consequences of oxidative stress generation in relation to liver fibrosis and its progression
101
Antioxidants: a possible tool to support conventional therapy for CLDs to reduce fibrosis progression?
107
Concluding remarks
108
7.
Role of Nitric Oxide in Liver Disorders
115-132
Pablo Muriel (Mexico)
Introduction
115
Nitric oxide and hepatic fibrosis
116
Nitric oxide and hyperdynamic circulation
117
Nitric oxide and paracetamol-induced liver injury
119
Nitric oxide, and liver inflammation and septic shock
120
Nitric oxide and hepatic ischemia-reperfusion injury
122
Role of nitric oxide in hepatocellular carcinoma
. 123
Nitric oxide effects on mitochondria and other
organelies
124
Concluding remarks
125
8.
Renin-Angiotensin System and Liver Fibrosis
133-140
Hitoshi Yoshiji, Shigeki Kuriyama and Hiroshi Fukui (Japan)
Introduction
133
Angiotensin II and liver fibrosis
135
Angiotensin II and angiogenesis
135
Angiotensin II and TIMP-1
136
Conclusions
138
Section
-
II.
Immunologicał
Basis of Liver Injury
9.
Cell and Molecular Mechanisms in the Development of Chronic Liver Inflammation
143-158
Simon
С
Afford and Patricia F. Lalor (UK)
Introduction
143
Triggering hepatic inflammation
145
Trafficking and retention of inflammatory cells in the liver and role of hepatic endothelium
146
Role of cholangiocytes and hepatocytes during Inflammation
149
Regulation of hepatic stellate cell function and survival
153
Potential targets for therapeutic intervention
154
10.
Role of Activated
Macrophages
in Liver Disease
159-178
ion V. Deaciuc and Craig J. McClain (USA)
Introduction
159
Markers of
macrophage
activation
160
Mechanisms of monocyte and Kupffer cell activation
162
Liver injury by
MC-
and
КС
-secreted mediators
165
Conclusions and future directions
171
CONTENTS
ІХ
11.
Basis for Immune Recognition of Cellular Targets in Primary Biliary Cirrhosis
179-196
Ruth Joplin (UK)
Introduction
179
Cellular targets in PBC
180
Antigenic targets in PBC
184
Models of PBC
187
Infectious agent as basis of immune recognition of cellular targets in PBC?
190
12.
Cross Talk of Hepatocytes and Nonparenchymal Liver Cells in Physiology and Pathology:
Monoxides and Eicosanoids
197-216
Zbigniew Kmieć
(Poland)
Nitric oxide in normal and diseased liver
197
Role of
heme
oxygenase and carbon monoxide in liver function
202
Eicosanoids in liver physiology and pathobiology
204
13.
Activity of Cytokines in Chronic HCV Infection and Influence of Antiviral Drags
217-226
Tadeusz Wojciech Łapinski
(Poland)
Introduction
217
Role of IL-1 in HCV infection
217
Implication of IL-12 in HCV infection
219
Role of IL-18 in HCV infection
219
Synergy of cytokines in activation of apoptosis
219
Significance of Thl and Th2 lymphocytes in HCV infection
220
Role of IL-2 in HCV infection
220
Significance of IL-15 in hepatitis
С
infection
220
IFN
-γ
activity in HCV infection
222
Role of IL-4 in HCV infection
222
Influence of HCV infection on IL-6 concentration
222
Activity of other cytokines in HCV infected patients
223
14.
Role of Chemokines in Liver Pathophysiology
227-242
Fabio Marra
(Italy)
Introduction
228
Alcoholic liver disease
230
Ischemia-reperfusion injury
230
Transplant rejection
231
Viral hepatitis
232
Other causes of liver inflammation
233
Liver cancer
234
Angiogenesis
234
Liver regeneration
234
Chemokines and the biliary system
235
Liver fibrosis
235
Conclusions
237
Volume
—2
Section
-
III. Clinical Liver Disease Pathophysiology
15.
Nonalcoholic Fatty Liver Diseases: Clinical and Pathophysiological Features
245-272
Frank A. Anania (USA)
Introduction
245
Primary and secondary causes of hepatic steatosis
—
macrosteatosis
246
Epidemiology of NAFLD and NASH
248
Pathogenesis of nonalcoholic fatty liver disease and steatohepatitis: current concepts
251
Rodent models of NAFL and NASH—/« vivo tools to study NAFLD
255
X LIVER DISEASES
Status of the utility of animal models
257
How is the diagnosis of NAFLD made?
259
Medical therapy for human fatty liver disease
261
Weight reduction for NAFLD: a multidisciplinary approach
262
Novel therapies specifically for NAFLD
265
Surgical therapy for NAFLD
266
16.
Genetic Basis of Hepatocellular Cancer
273-308
Sigal Tal-Kremer, Christopher P. Day and Helen L. Reeves
Introduction
273
Mechanisms of gene deregulation in HCC
274
Genetic instability in hepatocellular cancer
278
Cell cycle regulation and its disruption in HCC
281
Inactivation of p53
286
Wnt/ß-catenin
pathway
289
Apoptosis
291
Roles of various aetiologies of chronic liver disease in initiation and progression of HCC
295
Future directions
301
17.
Haemochromatosis: Recent Advances
309-330
AJM Dam s and WM Rosenberg-
Introduction
309
Iron biology
309
Genetics of HH-HFE
311
HFE epidemiology
311
HFE molecule
311
Effect of HFE mutations
313
Other genetic causes of iron overload
313
Rare HFE mutations
315
Other genes causing HH
315
Prevalence of HH
316
Role of HFE in other liver disorders
320
Role of HFE in extrahepatic disorders
320
Advances in diagnosis
322
Management of HFE
322
Screening for HH
324
Concluding remarks
324
18.
Pathophysiology of Cirrhotic
Ascites:
Recent Advances
331-350
George Therapondos and Florence Wong
Introduction
331
Historical perspective
331
Currently accepted hypothesis: peripheral arterial
vasodilatation
332
Evolving concepts
332
Pathogenesis of sodium retention at various stages of cirrhosis
343
19.
Cryptogenic Hepatitis
351-366
Isabelle Chemin
Introduction
351
Diagnostic settings
352
External agents
352
Common aetiologies to eliminate
352
Other forms of cryptogenic hepatitis
354
Identification of new hepatitis viruses
357
Candidates viruses in the field of cryptogenic hepatitis
357
Conclusion
361
CONTENTS
ХІ
20. HIVl
and the Liver
367-378
Sandro
Vento, M.D. and Francesca Cainelli, M.D.
Introduction
367
Peculiar aspects of the liver in HIVl infection
367
Hepatitis
В
Virus infection in HIV-infected patients
368
Hepatitis
D
and HIVl infection
370
Hepatitis
С
Virus infection in HIVl-infected patients
371
Antiretroviral drugs and the liver
373
Conclusions
373
21.
Cell Death by Necrosis: Mechanisms and Interception in the Liver
379-398
Shakir AH
Introduction
379
Liver necrosis: a cytolytic injury
380
Necrosis vs apoptosis, and autolysis
381
Mechanisms of liver necrosis
382
Deranged biochemical, cellular and molecular pathways in liver necrosis
389
Biochemical manifestations of liver necrosis
392
Liver necrosis: Interception
393
22.
Fulminant Hepatic Failure: Etiology, Pathogenesis, and Treatment
399-420
Eran
Elinav and Rafael
Brück
Introduction
399
Definition
400
Pathophysiology
400
Etiology
400
Clinical manifestations
403
Evaluation
405
Treatment
406
Prognosis
408
Liver transplantation
409
Extracorporeal hepatic replacement systems
410
Conclusion
412
Section
-
IV. Therapeutic and Diagnostic Insights
23.
Advances in Biology and Therapy of Hepatitis
В
Virus Infection
423-438
Frank
Tacke,
Michael P. Manns and Christian
Trautwein
Introduction
423
Hepatitis
В
virus genome and Proteins
423
Hepatitis
В
virus life cycle
424
Hepatitis
В
virus mutants
427
Current vaccination and treatment strategies
430
Novel antiviral strategies and future directions
431
Conclusions
434
24.
Hepatitis
С
Virus: Molecular Virology and Therapeutic Targets
439-458
Andrew
Macdonald
and Mark Harris
Introduction
439
Genome of HCV
440
Functions of HCV polypeptides in viral replication
440
HCV replication cycle
442
Study of HCV replication
—
problems and solutions
443
Current therapies for HCV infection
446
Pathogenic mechanisms
447
Concluding remarks
453
XU
LIVER DISEASES
25.
Drag Targeting to Hepatic Stellate Cells: A New Strategy to Treat Liver Fibrosis
459-474
Leonie Beljaars,
Dirk K.F. Meijer
and
Klaas Poelstra
Introduction
459
Liver fibrosis and hepatic stellate cells
460
Antifibrotic drugs and hepatic stellate cells
460
Drug targeting: problems and possibilities
461
Drug targeting to hepatocytes, Kupffer cells, and endothelial cells in relation to liver fibrosis
464
Hepatic stellate cell
—
selective therapy: emerging prospects
465
Important considerations for drugs to be targeted
466
Drugs targeted to hepatic stellate cells
470
Perspectives
471
26.
Developing Therapeutic Strategies for Hepatic Fibrosis
475-488
Ichiro Shimizu
Introduction
475
Oxidative stress in liver injury
476
Immunity in liver injury
476
Oxidative stress and HSC activation
476
Antioxidant
protective mechanisms
477
Hepatic steatosis
478
HSC activation and ECM
478
Growth factors
478
HSC contractility
479
Termination of HSC activation
479
Antifibrotic therapy
479
Conclusions
484
27.
Liver Disease, Oxidative Stress and Ursodeoxycholic Acid
489-510
Predrag Ljubuncic
and Arieh Bomzon
Introduction
489
Mitochondria: the machines of cell survival
491
Apoptosis or programmed cell death
491
Apoptosis and oxidative stress
493
Liver disease and bile acids
496
Ursodeoxycholic acid (UDCA)
498
Conclusion
502
28.
Plasma
TGF-ß
as a Diagnostic and Prognostic Marker
511-518
M. Antoine, M.
Mavituna,
R.
Weiskirchen,
A.M. Gressner and P.
Kiefer
Introduction
511
Methods to measure
TGF-ß
concentrations in plasma
512
Changes in plasma levels of TGF and human disease
514
Concluding remarks
516
29.
Hepatocytes as the Gold Standard for Predicting in vivo Hepatotoxicity of Xenobiotics Using Accelerated
Cytotoxicity Mechanism Screening Techniques
519-530
Peter
}.
O Brien,
Arno
Široki,
Shahrzad Tafazoli and Katie Chan
Introduction
519
Application of in vitro hepatocyte cytotoxicity research to determine molecular mechanisms
of in vivo xenobiotic-induced liver
toxicity
520
Literature review of hepatotoxic mechanisms of halobenzene derivatives
520
Comparison of hepatotoxicity and
toxicity
mechanisms of halobenzene derivatives in vivo
522
Accelerated Cytotoxic Mechanism Screening with hepatocytes
523
Comparison of hepatocyte cytotoxicity and molecular cytotoxic mechanisms of xenobiotics in vitro using an
ACMS/QSAR approach
523
Idiosyncratic hepatotoxicity promotion by inflammation, H,O2 and peroxidases
527
Conclusions
527
Index
531-540
About the Book
There have been major advances in our understanding of the liver, and a growing
number of mechanisms underlying liver diseases continue to pose new challenges. This
book presents state-of-the-art information summarizing the current understanding of a
range of liver diseases and reviews some key diagnostic and therapeutic advances.
The book constitutes a collection of selected clinical and scientific topics divided into two
volumes, each divided into two sections. The first volume treats the cellular, biochemical
and immunological mechanisms underlying liver diseases; the second focuses on clinical
liver disease pathophysiology and related diagnostics and therapeutic insights.
Collectively, the two volumes represent a broad range of important topics but are not
intended as a comprehensive summary of all domains in liver research and diseases.
It is hoped that the target readers
—
hepatologists, clinicians, researchers and
academicians
—
will be afforded new ideas and exposed to subjects well beyond their own
scientific disciplines. In addition, students and all those who wish to enlarge their
knowledge of advances in the field of liver diseases should find this book a valuable source
ofinformation.
About the Editors
Shakir
Ali,
Ph.D. is a Reader at the Department of Biochemistry, Jamia Hamdard (Deemed
University) at New Delhi (India). He has published papers on the mechanisms of tissue
injury in noncommunicable diseases, and has been associated with several research
projects including
a
UNICEF
sponsered
multicenter
study. Dr.
Ali
has identified
molecules such as boron and tungsten as metabolic interceptors in various forms of
liver injury. Dr. AH was awarded Commonwealth Fellowship Award by the
Commonwealth Scholarship Commission in the United Kingdom.
Scott L.
Friedman, M.D.,
Ph.D. is the Fishberg Professor and Chief of Liver Diseases at
Mount Sinai School of Medicine (USA), and has performed pioneering research into the
mechanisms of hepatic fibrosis. Professor Friedman was a Fulbright Scholar at the
Weizmann Institute of Science in
1995,
and was awarded the international Hans Popper
Award by the
Falk
Foundation in
2003
in recognition of his outstanding contributions to
the understanding of liver diseases and its treatment.
Derek A. Mann, Ph.D. is the Professor of Molecular Biology, and Head, University of
Southampton Liver Research Group (UK) that has made seminal discoveries concerning
the biology of liver fibrosis. His most important contributions concern the
transcriptional regulation of hepatic stellate cell phenotype and the discovery that
stimulation of apoptosis of hepatic stellate cells promotes the resolution of fibrosis.
Professor Mann has published in excess of
60
peer-reviewed papers and has filed several
international and US patents relating to technologies for the treatment of liver fibrosis.
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV023023153 |
| callnumber-first | R - Medicine |
| callnumber-label | RC846 |
| callnumber-raw | RC846.9 |
| callnumber-search | RC846.9 |
| callnumber-sort | RC 3846.9 |
| callnumber-subject | RC - Internal Medicine |
| ctrlnum | (OCoLC)61351602 (DE-599)BVBBV023023153 |
| dewey-full | 616.3/62 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.3/62 |
| dewey-search | 616.3/62 |
| dewey-sort | 3616.3 262 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01460nam a2200337 cc4500</leader><controlfield tag="001">BV023023153</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20080125 </controlfield><controlfield tag="007">t|</controlfield><controlfield tag="008">071127s2006 xx ad|| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1578084008</subfield><subfield code="9">1-57808-400-8</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)61351602</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV023023153</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC846.9</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.3/62</subfield><subfield code="2">22</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Liver diseases</subfield><subfield code="b">biochemical mechanisms and new therapeutic insights</subfield><subfield code="n">1</subfield><subfield code="p">Pathways, mediators and regulation</subfield><subfield code="c">ed.: Shakir Ali ...</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Enfield, NH [u.a.]</subfield><subfield code="b">Science Publ.</subfield><subfield code="c">2006</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XIX, 242 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Liver Diseases</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Liver</subfield><subfield code="x">Pathophysiology</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ali, Shakir</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="w">(DE-604)BV023023150</subfield><subfield code="g">1</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">Digitalisierung UB Regensburg</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016227175&sequence=000003&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">Digitalisierung UB Regensburg</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016227175&sequence=000004&line_number=0002&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Klappentext</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-016227175</subfield></datafield></record></collection> |
| id | DE-604.BV023023153 |
| illustrated | Illustrated |
| indexdate | 2024-12-23T20:43:45Z |
| institution | BVB |
| isbn | 1578084008 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-016227175 |
| oclc_num | 61351602 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | XIX, 242 S. Ill., graph. Darst. |
| publishDate | 2006 |
| publishDateSearch | 2006 |
| publishDateSort | 2006 |
| publisher | Science Publ. |
| record_format | marc |
| spellingShingle | Liver diseases biochemical mechanisms and new therapeutic insights Liver Diseases Liver Pathophysiology |
| title | Liver diseases biochemical mechanisms and new therapeutic insights |
| title_auth | Liver diseases biochemical mechanisms and new therapeutic insights |
| title_exact_search | Liver diseases biochemical mechanisms and new therapeutic insights |
| title_full | Liver diseases biochemical mechanisms and new therapeutic insights 1 Pathways, mediators and regulation ed.: Shakir Ali ... |
| title_fullStr | Liver diseases biochemical mechanisms and new therapeutic insights 1 Pathways, mediators and regulation ed.: Shakir Ali ... |
| title_full_unstemmed | Liver diseases biochemical mechanisms and new therapeutic insights 1 Pathways, mediators and regulation ed.: Shakir Ali ... |
| title_short | Liver diseases |
| title_sort | liver diseases biochemical mechanisms and new therapeutic insights pathways mediators and regulation |
| title_sub | biochemical mechanisms and new therapeutic insights |
| topic | Liver Diseases Liver Pathophysiology |
| topic_facet | Liver Diseases Liver Pathophysiology |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016227175&sequence=000003&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016227175&sequence=000004&line_number=0002&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV023023150 |
| work_keys_str_mv | AT alishakir liverdiseasesbiochemicalmechanismsandnewtherapeuticinsights1 |